Description
Release form
Tablets
packaging
80 pcs
Pharmacological action
Penester is a drug for the treatment of benign prostatic hyperplasia. Finasteride is a synthetic 4-azasteroid compound. It is a competitive and specific inhibitor of steroid 5-alpha reductase, an intracellular enzyme that converts testosterone to the active androgen 5-dihydrotestosterone. The growth of prostate tissue and the development of benign hyperplasia are due to the conversion of testosterone to dihydrotestosterone in the cells of the prostate gland. Under the influence of the drug, a significant decrease in the concentration of dihydrosterone occurs in both blood plasma and gland tissue. Finasteride does not bind to androgen receptors.
As a result of the use of the drug, the size of the prostate gland decreases, the severity of symptoms associated with prostatic hyperplasia decreases.
The drug does not affect the concentration of plasma lipids, as well as the plasma content of cortisol, estradiol, prolactin, thyroid stimulating hormone, thyroxine.
Pharmacokinetics
Absorption and distribution of
After oral administration, finasteride is rapidly absorbed from the digestive tract. Bioavailability is about 80% and is independent of food intake. Cmax in blood plasma is achieved 1-2 hours after ingestion of the drug. Plasma protein binding is about 90%.
Metabolism and excretion
Finasteride is metabolized in the liver and excreted as metabolites in urine and feces.
Pharmacokinetics in special clinical cases
T1 / 2 in patients older than 60 years is 6 hours, in patients older than 70 years it can be extended up to 8 hours
Pharmacodynamics
Compensates insufficiency of exocrine pancreatic function, has proteolytic, amylolytic and lipolytic effects.
Pancreatin-containing enzymes (lipase, alpha-amylase, trypsin, chymotrypsin) help break down proteins to amino acids, fats to glycerol and fatty acids, starch to dextrins and monosaccharides. Improves the functional state of the digestive tract, normalizes digestion processes.
Trypsin inhibits the stimulated secretion of the pancreas, providing an analgesic effect.
Pancreatic enzymes are released from the dosage form in the alkaline environment of the small intestine, because protected from the action of gastric juice by the membrane.
Maximum enzymatic activity is noted 30 45 min after oral administration.
Indications
replacement therapy for exocrine pancreatic insufficiency (chronic pancreatitis, pancreatectomy, post-irradiation, dyspepsia, Remkheld s syndrome (gastrocardial syndrome), cystic fibrosis)
flatulence, gastrointestinal diarrhea and necrotic disease )
to improve the digestion of food in people with normal gastrointestinal function in case of errors in nutrition (eating fatty foods, large amounts of food, irregular molecular weight food) and for violations of the chewing function, sedentary lifestyle, prolonged immobilization
preparation for X-ray examination and ultrasound of the abdomen.
Contraindications
hypersensitivity to the drug
acute pancreatitis
exacerbation of chronic pancreatitis.
Use during pregnancy and lactation
The safety of pancreatin during pregnancy has not been sufficiently studied. Use is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus.
Special instructions
The safety of pancreatin use during pregnancy has not been sufficiently studied. Use is possible in cases where the expected benefit to the mother outweighs the potential risk to the fetus. In case of cystic fibrosis, the use of pancreatin in high doses is not recommended due to an increased risk of developing strictures (fibrotic colonopathy). The dose should be adequate to the amount of enzymes necessary for fat absorption, taking into account the quality and quantity of food consumed. With prolonged use, iron preparations are prescribed at the same time.
Composition
1 tablet contains:
Active ingredient: Pancreatin
Excipients: lactose, microcrystalline cellulose, sodium starch glycolate, polyvinylpyrrolidone, talc, colloidal silicon dioxide, methacrylic acid copolymer, diethyl phthalate, titanium dioxide.
Dosage and Administration
Inside. Penzital is taken during or after meals without chewing and drinking with non-alkaline liquids (water, fruit juices).
Dose is determined individually, depending on the degree of digestion. Adults usually 1-2 tablets 3 times a day.
In children, the drug is used as directed by a doctor. The duration of treatment can vary from a few days (if the digestive process is disturbed due to errors in the diet) to several months or years (if constant replacement therapy is necessary).
Side effects of
Allergic reactions. In some cases, diarrhea, constipation, discomfort in the stomach, nausea (a causal relationship between the development of these reactions and the action of pancreatin has not been established, because these phenomena relate to symptoms of exocrine pancreatic insufficiency). With prolonged use in high doses, the development of hyperuricosuria, an increase in the level of uric acid in the blood plasma are possible. With cystic fibrosis, if the required dose of pancreatin is exceeded, strictures (fibrotic colonopathy) may develop in the ileocecal section of the ascending colon. When using pancreatin in high doses in children, perianal irritation and irritation of the oral mucosa are possible.
Drug interaction
With the simultaneous use of pancreatin with iron preparations, a decrease in absorption of the latter is possible. The simultaneous use of antacids, containing calcium carbonate and / or magnesium hydroxide, may reduce the effectiveness of pancreatin.
Overdose
Symptoms of hyperuricosuria, hyperuricemia. In children – constipation.
Treatment: withdrawal of the drug, symptomatic therapy.
Storage conditions
At a temperature not exceeding 25 ° C, in a dry place out of the reach of children.
Shelf life
3 years
Deystvuyushtee substance
Pancreatin
Terms and conditions
without prescription
dosage form
tablets
Possible Product Names
Penzital Tablets Coated. Solution-Sol. 80 pcs.
